Introduction
Despite progress in antibiotic treatment, mechanical ventilation, fluid resuscitation and blood glucose maintenance, sepsis remains high mortality in the intensive care unit (ICU) (Mayr et al, 2014) . Over the past 40 years, there has been a concerted effort to recognize factors in the host response to infection that could potentially serve as targets for therapeutic manipulation. Despite the more than 100 clinical trials regarding sepsis treatments that have been conducted, no US Food and Drug Administration (FDA)-approved treatment strategies currently exist for the routine management of septic patients. Key factors of developing sepsis include release of pro-inflammatory mediators, diffuse endothelial injury and pro-coagulant reactions, followed by organ dysfunction.
Increasing evidence indicates an extensive interaction between inflammation and coagulation that may play a vital role in the pathophysiology of sepsis (Levi & van der Poll, 2015) . The pro-inflammatory mediators activate coagulation, which promotes inflammatory activity in many ways (Opal, 2000) . More commonly, the coagulation cascade interacts with the inflammatory pathway and induces activation of endothelial cells, which may express a pro-coagulant phenotype. Increasing production of inflammatory mediators and leucocyte adhesion result in secondary dysfunction of internal organs (Camerota et al, 1998) .
The clotting cascade begins with expression of tissue factor (TF) on circulating monocytes, tissue macrophages, and possibly subsets of endothelial cells (Pernerstorfer et al, 1999) . It is up-regulated in sepsis through both activation by proinflammatory mediators and failure of regulatory mechanisms, such as tissue factor pathway inhibitor (TFPI) (Hunt, 2014) . TF triggers the extrinsic pathway of the coagulation system and induces the generation of thrombin, which modulates formation of fibrin and acts as a potent platelet agonist, all of which further enhance pro-inflammatory activities. Meanwhile, sepsis inhibits many of the natural anticoagulant mechanisms. Circulating levels of protein C (PC) and anti-thrombin III (ATIII) are reduced (Suffredini et al, 1989; Philippe et al, 1991) . Sepsis-mediated down-regulation of thrombomodulin (TM) on the endothelial cell surface may attenuate activation of PC (Faust et al, 2001 ). In addition, fibrinolysis becomes suppressed by the up-regulation of its main inhibitor, plasminogen activator inhibitor-1 (PAI-1) (Schleef et al, 1988) . Thus, the fibrinolytic system is less active than the clotting system and fibrin clots will accumulate in the microcirculation. Such a consumptive state represents the coagulation disturbances in which the rate of platelet and coagulation factors consumption exceeds the body's synthesis of these components. Consequently, concentrations of platelet and coagulation factor lessen steadily, ultimately leading to an imbalance of the physiological haemostasis system. This process leads to sepsis-induced coagulation disturbances, such as local or diffuse microvascular thrombi, thrombocytopenia, disseminated intravascular coagulation (DIC) and organ dysfunction (Dhainaut et al, 2005) . It has been demonstrated that the most important mediators for orchestrating this imbalance of the haemostasis system during sepsis are cytokines (Levi et al, 1997) .
Actually, almost all septic patients have coagulation abnormalities. These abnormalities range from subtle coagulation activation that can only be detected by sensitive markers, to somewhat stronger ones, such as decrease in platelet count and subclinical prolongation of global clotting times to fulminant DIC (Levi et al, 1993; Levi, 2008) . The basis of the treatment of coagulation in sepsis is the specific and vigorous management of the underlying disorder. Unfortunately, simple inhibition of microthrombosis and consumptive coagulopathy by selective blockade of thrombin generation did not prevent lethality in sepsis or septic shock (Levi & van der Poll, 2008) . Recognizing that inflammation and coagulation are inextricably linked and the interaction contributes to the pathophysiology of sepsis, it is no surprise that in the quest to improve the outcome in sepsis, much attention has been directed to agents that attenuate the activation of both inflammation and coagulation. Apart from the well-known anticoagulant effects of heparin, several studies have indicated that heparin possesses various biological properties, such as anti-inflammatory and immunomodulatory effects (Young, 2008; Ludwig, 2009 ). Hence, heparin seems to be such an agent. This review assembles the available pre-clinical and clinical data supporting the use of heparin in sepsis.
The anticoagulant mechanism of action
Heparin is a glycosaminoglycan with anticoagulant properties and anti-inflammatory effects. Following its discovery in 1916 and early clinical practice in the late 1930's (Jorpes, 1935; Crafoord, 1937) , it has been extensively used in clinical practice for various indications, especially for the prevention and treatment of venous thromboembolism (VTE).
Coagulation is a complicated process including platelets, soluble proteins and cellular components, such as monocytes and endothelial cells (Versteeg et al, 2013) , and haemostasis is maintained by the balance between clotting factors and coagulation inhibitors. The main plasma coagulation inhibitor is AT, which targets activated coagulation factors, such as factors XIIa, XIa, Xa, IXa, VIIa and thrombin.
Heparin interacts with the coagulation system in multiple ways, but its interplay with AT for inhibiting the action of thrombin and factor (F) Xa, is unique. It is clear that the active centre serine of thrombin and other coagulation enzymes are inhibited by an arginine-reactive site on the AT molecule. Heparin exerts an anticoagulant effect by binding to the lysine site on AT, thereby inducing a non-reversible conformational change at the arginine-reactive site in such a manner that it inhibits thrombin by up to 1000 times (Alban, 2015) . Given that a ternary complex must be formed simultaneously between heparin, AT and thrombin, the inhibition of thrombin requires a heparin chain comprising of at least 18 saccharide units. Therefore, it can occur with unfractionated heparin (UFH) but not with low-molecular weight heparin (LMWH) (Hirsh et al, 2001) . Additionally, UFH binds to heparin cofactor II, further reducing the activity and availability of thrombin (Hollenstein et al, 2002) . Once UFH has accelerated the activity of AT, it can dissociate from the ternary complex and bind to other AT molecules, thereby exerting a continuing anticoagulant effect. Only 30% of UFH chains contain the sequence necessary for activating AT, which is responsible for most of its anticoagulant effect (Andersson et al, 1976) . The heparin-AT complex inactivates a quantity of coagulation enzymes, involving thrombin, factors Xa, IXa, XIa and XIIa (Alban, 2015) . Among these, thrombin and FXa are the most critical and responsive within the clotting cascade. And thrombin is about 10-fold more sensitive to inhibition by the heparin-AT complex than FXa. UFH also suppresses thrombin-induced activation of FV and FVIII and promotes the release of TFPI, which decreases the pro-coagulant activity of the TF-VIIa complex (Hirsh et al, 2001) . The anticoagulant effects of heparin are summarized in Table I and Fig 1. UFH is an indirect anticoagulant because it entirely depends on AT. Thus, AT depletion is one reason for the lack of response to heparin therapy. Many DIC patients have AT depletion secondary to accelerated thrombin generation (Moore & Hinchcliff, 1994) . The anticoagulant effect of heparin is also modulated by plasma proteins, fibrin, platelets and vascular surfaces. Platelets restrict the anticoagulant effect of heparin by protecting surface FXa from inhibition by the AT-heparin complex (Marciniak, 1973) and by secreting platelet factor 4 (PF4), a heparin-neutralizing protein (Lane et al, 1986) . Fibrin restricts the anticoagulant effect of heparin because the heparin-AT complex is relatively large and unable to inactivate fibrin-bound thrombin (Hirsh et al, 2001) . UFH has no fibrinolytic activity, so it has no effect on existing clots.
Immunothrombosis affects the timing of heparin
Activation of the coagulation system and thrombosis in sepsis are normally regarded as adverse events because they compromise the blood supply to organs. However, recent studies have shown that local thrombosis in answer to microorganisms is actually an independent line of the early innate immune defence against invading pathogens (Engelmann & Massberg, 2013; Pfeiler et al, 2014) . This defensive clot formation is actually good for the host and is now referred to as immunothrombosis (Engelmann & Massberg, 2013) . Immunothrombosis is, in some degree, a result of the evolutionary conserved link between coagulation and innate immunity (Loof et al, 2011a,b) . It mediates the recognition of pathogens and damaged cells, and inhibits pathogen dissemination and survival. Activated neutrophils and monocytes are two main inducers of immunothrombosis. Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) in the early phase of sepsis induce TF expression on monocytes and neutrophil extracellular trap (NET) release by neutrophils; they both promote immunothrombosis (Ito, 2014) .
To date, immunothrombosis serves at least four different physiological functions in impeding the dissemination and tissue invasion of pathogen. First, it restricts microbial dissemination by retaining the microorganisms within thrombi. At this point, FXIII crosslinks bacteria to fibrin fibres, resulting in immobilization and killing of bacteria inside the clots (Loof et al, 2011a) . Second, it prevents tissue invasion through the formation of protective barricades inside and/or around blood vessels (Massberg et al, 2010) . Third, the microvascular accumulation and deposition of fibrinogen, fibrin and fibrin/fibrinogen degradation products promote the recruitment and activation of immune cells, such as neutrophils and macrophages, to the sites of infection, further recognizing pathogens and coordinating the immune response (Szaba & Smiley, 2002; Flick et al, 2004) . Fourth, the intravascular thrombi form a distinct compartment that focuses antimicrobial peptides and their pathogen targets, and thus favours pathogen killing. Antimicrobial peptides can be produced during the activation of blood coagulation and/or released by activated platelets or leucocytes during the process of immunothrombosis (Frick et al, 2006; Vieirade-Abreu et al, 2012) .
The coagulation system and innate immunity system work closely together (Delvaeye & Conway, 2009 ). However, although immunothrombosis plays a beneficial role in early host defence against bacterial dissemination, aberrant or uncontrolled immunothrombosis may be detrimental to the host (Ito, 2014) . Thus, it remains to be determined whether anticoagulant therapy, such as heparin, improves the clinical outcomes of septic patients and the proper timing.
Immunomodulation
Severe infection rapidly activates systemic host defences, including the coagulation, complement and immune systems. Activation of several different types of inflammatory cells promotes the release of pro-inflammatory mediators, leading to further amplification of the immune response. Concomitant microvascular thrombi formation and platelet activation induce local tissue ischaemia and further exacerbate the inflammatory response. Although the host produces endogenous anti-inflammatory and anticoagulant mediators, it is often inadequate to attenuate the devastating effects of global inflammation and tissue ischaemia in sepsis. In recent years, several animal studies and clinical trials have suggested that heparin also possesses other properties besides anticoagulation, including (but not limited to) anti-inflammatory actions, anti-complement activity and modulation of various proteases (Davidson et al, 2002; Hoppensteadt et al, 2008) . Although the anticoagulant mechanisms of heparin are well understood, those underlying its anti-inflammatory and immunomodulatory effects in sepsis are not. Ding et al (2011) indicated that UFH could attenuate inflammation and coagulation and prevent lethality in endotoxemic mice. Several experimental studies have shown important immunomodulatory activity of heparin with modulating platelet activation (Anaissie et al, 1998) , leucocyte recruitment (Eggimann et al, 2003) , lipopolysaccharide (LPS)-stimulated release of cytokines (Blot et al, 2002) , expression of adhesion molecules (Rex et al, 2000) , and angiogenesis (Brassart et al, 1991) . Heparin modulates pulmonary hypertension, hypoxaemia, neutrophil migration, and oedema formation in endotoxaemic models (Hocking et al, 1992; Meyer et al, 1993; Darien et al, 1998) . Moreover, heparin can inhibit specific neutrophil functions, such as chemotaxis and superoxide generation in vitro, as well as reduce eosinophil migration and decrease vascular permeability (Hiebert & Liu, 1990; Bazzoni et al, 1993; Teixeira & Hellewell, 1993) . During sepsis, cell adhesion between neutrophils and endothelium is a vital event preceding neutrophil trans-endothelial migration from the blood circulation into tissues. There is increasing evidence that heparin interferes with the key first step in sepsis, which is the adhesion of leucocytes to the endothelium. In addition, our previous studies found that treatment with UFH can attenuate LPS-induced inflammatory responses in vivo and in vitro (Li et al, 2012 (Li et al, , 2013 (Li et al, , 2015 . The mechanism seems to correlate with its inhibition of inflammatory mediators production via inactivation of nuclear factor-jB (NF-jB), which plays a central role in triggering and coordinating both innate and adaptive immune responses. Wildhagen et al (2014) described a novel and interesting immune-modulating mechanism of heparin in vitro and showed in septic mouse models that non-anticoagulant heparin may exert a protective effect by blocking circulating histones. Heparin has a strong affinity for extracellular histones that result from cellular destruction during severe inflammation. The histones are robustly associated with endothelial dysfunction, organ dysfunction and even death during sepsis (Xu et al, 2009 ). Moreover, Iba et al (2015) reported that both UFH and LMWH suppressed the toxicity of histone H 3 , both in vivo and in vitro. Heparin at high concentrations prevents the interaction between histone and platelets, which is a potential therapeutic target to regulate inflammation in sepsis (Fuchs et al, 2011; Alhamdi et al, 2016) . But the exact benefit and safety of heparin and its derivatives as anti-inflammatory agents in clinical setting are yet to be described. The immunomodulatory effects of heparin are summarized in Table I and Fig 1. Early points of sepsis as a simply hyper-inflammatory state that could be modulated by breaking one step in the continuing process (e.g., administering antibody against tumour necrosis factor) have turned out to be too simplistic. Actually, in the later stages of sepsis, the body is relative immunosuppressive (immunoparalysis), characterized by extremely low concentrations of pro-inflammatory mediators. Thus further suppression of inflammation might be harmful rather than beneficial (Polderman & Girbes, 2004) . This complex cascade suggests that targeting single steps in sepsis is unlikely to be effective. Thus, both inhibition of the production of inflammatory mediators and interruption of microthrombi formation could be crucial for decreasing inflammatory responses and attenuating tissue ischaemia in sepsis. These observations raise the possibility that heparin may be effective in septic patients, and it is of urgent importance to elucidate the mode of action, proper timing, proper dosage etc.
Glycocalyx
The endothelial cells line the interior surface of all blood vessels. Endothelial cells have an outer layer of glycocalyx, which is a complex network of macromolecules. The core protein of glycocalyx is syndecan-1, which has attached glycosaminoglycans (GAGs) (Henrich et al, 2010) . Heparan sulphate (HS) is the main component of GAGs. The dysfunction of endothelial cells and the reduction of glycocalyx are key characteristics of sepsis. The glycocalyx plays a crucial role in endothelial and microvascular physiology, especially by regulating endothelial permeability and microvascular tone, maintaining an oncotic gradient across the endothelial barrier, regulating adhesion and migration of neutrophils and interrupting intravascular thrombosis (Woodcock & Woodcock, 2012; Frati-Munari, 2013) . Vascular permeability is modulated by a double barrier. The degradation of glycocalyx increases capillary permeability, leading to tissue oedema, indicating that the glycocalyx acts as a competent component in addition to the barrier formed by the endothelial cells themselves (Rehm et al, 2004) . Despite the increasing evidence that glycocalyx is responsible for sepsis-related altered vascular permeability, its actual clinical efficacy still needs to be proven. Sun et al (2015) showed, in a canine septic shock model, that a therapeutic dose of UFH could protect glycocalyx from shedding by suppressing inflammation. The underlying mechanism may be that UFH, as an HS analogue, may reconstitute cell surface by mobilising an intercellular pool of syndecan-1, which can reconstruct the protective network of proteoglycans to re-establish an effective vascular barrier (Nelson et al, 2008) . The effects of heparin on glycocalyx are summarized in Table I 
Clinical trials
Interest in heparin as a therapeutic agent in sepsis was spurred by the observation that the use of low dose prophylactic heparin in the placebo arms of KyberSept (phase 3 AT trial) (Warren et al, 2001 ) was associated with a tendency for decreased mortality, although this was not statistically significant. The PROWESS study (Bernard et al, 2001 ) was the first to suggest a survival benefit of heparin in ICU patients with severe sepsis that aimed to regulate the host inflammatory response in sepsis. This result is based on a subgroup analysis and needs to be tested. The OPTIMIST study (Abraham et al, 2003) , investigated the potential benefits of recombinant TFPI in severe sepsis and observed that treatment with UFH alone (for reasons unrelated to sepsis) lowered mortality. These observations should be interpreted with caution. The administration of heparin was a post-randomization event and thus heparin might have been used more commonly in less severely ill patients. And the potential for selection bias is unavoidable because investigators initiated heparin on account of clinical need. It is also unknown whether baseline characteristics were comparable between the groups or not. Thus, we cannot conclude that heparin might have a beneficial therapeutic effect in sepsis from studies aimed to investigate the efficacy of other compounds due to both selection bias and allocation bias. Yet, this is not to say that heparin cannot possibly have a therapeutic role in sepsis. Zarychanski et al (2008) performed a retrospective propensity-matched study of 695 patients with septic shock. They found that intravenous administration of heparin was associated with decreased 28-day mortality (40Á1% and 44Á2%). Thus they concluded that early systemic heparin therapy could be an effective treatment for patients suffering from severe sepsis. Their results were corroborated by post hoc analysis of human trials, which investigated anticoagulants for severe sepsis (Polderman & Girbes, 2004) . A subsequent prospective randomized double blind study (HETRASE; Jaimes et al, 2009) of 319 septic patients were randomized to intravenous heparin or placebo. There was no significant difference in the primary outcome, which was duration of hospital stay. Furthermore, heparin-treated patients were unable to demonstrate a more rapid improvement in organ failure score or benefit in survival, although heparin treatment was safe as there was no increased risk of bleeding (Jaimes et al, 2009 ). There were several limitations in this study. First, 28-day mortality was not considered a primary endpoint. Second, this study included less-severely ill patients and a more heterogeneous population. Third, the heparin dose used (500 units/h without a bolus) may be inadequate in sepsis. No significant difference in activated partial thromboplastin time (APTT) was seen between the treatment and control groups. Fourth, this study included patients both with and without overt DIC. All of these may affect the way the results of this study are viewed. Recently, Yamakawa et al (2016) reported a post hoc subgroup analysis of a multicentre nationwide retrospective cohort study [the Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) registry]. Therapeutic effects of anticoagulants (e.g., AT, heparin) on 2663 consecutive adult patients with sepsis from 42 ICUs in Japan were evaluated by stratifying patients according to DIC and Sequential Organ Failure Assessment (SOFA) score. After adjustment for imbalances, anticoagulant treatment was obviously associated with reduced mortality only in subgroups of patients with sepsis-induced coagulopathy and/or who were very severely ill. These results may partly explain the negative conclusion from HETRASE Study (Jaimes et al, 2009) . Four systematic reviews and meta-analyses have been published to date regarding the use of heparin as a potential treatment for septic patients Wang et al, 2014; Zarychanski et al, 2015; Fan et al, 2016) . A remarkable result in all these four systematic reviews was that treatment with low doses of heparin was associated with significantly reduced 28-day mortality in sepsis. In the study by Wang et al (2014) , 40% of the study group patients used UFH exclusively, the rest used either UFH or LMWH. Among the study group patients analysed by Zarychanski et al (2015) , 151 of the 1325 patients used UFH exclusively (11%), the rest used LMWH, both UFH and LMWH or the combination of either UFH or LMWH with activated protein C (APC). Fan et al (2016) reported the efficacy and safety of LMWH exclusively in septic patients. Wang et al (2014) showed a 40% mortality reduction with the use of prophylactic heparin. However, Zarychanski et al reported a 12% relative risk reduction in mortality in patients receiving intravenous heparin. The trend for beneficial survival was also observed when the data were analysed by the type of heparin used and by different geographic areas. This meta-analysis included only trials in which patients were randomized to receive heparin or not. But the time periods of these trials ranged from 1983 to 2014 and included different definitions of sepsis, which may influence the results. In the study by Wang et al (2014) , non-randomized controlled trials accounted for most of the weight on mortality and bleeding events. The use of heparin was not randomized, which might explain the conflicting results for these two meta-analyses. Effects of heparin in clinical trials in sepsis are summarized in Table II .
Despite the conflicting results that have been reported, the value of heparin in the treatment of sepsis has gained increasing interest, and overall there seems to be a beneficial effect of heparin therapy in sepsis. Over many years of clinical use, heparin has been an extremely safe drug, particularly considering its biological origin and its heterogeneity. The central concern, as with all anticoagulants, is the potential risk of major haemorrhage. Besides bleeding, the main adverse effect of heparin is heparin-induced thrombocytopenia (HIT). Furthermore, 85% of the septic patients had hypoperfusion, in which cases the subcutaneous route is less preferable because of poor absorption. This might have attenuated the efficacy of heparin because of poor bioavailability. In order to have an influence on daily clinical practice, the clinician should know which compound and dose should be used, together with the route and proper timing of drug administration. None of the four meta-analyses answers these questions. Whatever, the results are a remarkable boost to further investigate the role of heparin in sepsis. The time is ripe for the design and conduct of a prospective randomized controlled double-blind clinical trial to evaluate the potential benefit and safety of heparin given in various doses and routes of administration in septic patients to confirm or refute this hypothesis.
Conclusion
The findings on heparin therapy in septic patients have generated many controversies in the medical literature. Additional to its well-known anticoagulant effects, UFH has significant immunomodulatory effects. It is currently unclear as to whether heparin is a vital adjunctive therapy in the management of sepsis. Future clinical trials of heparin treatment for sepsis might concentrate on the very severely ill patients with high expected mortality, as this is the group in which benefit is most likely to be proved. Furthermore, several open questions are ongoing about up-to-date proper patients, proper timing, proper dosages and administration schemes. Apart from the potential to decrease mortality from sepsis, the use of heparin in sepsis has international humanitarian significance. It would result in substantial cost savings and be a novel therapeutic choice with a potentially wide application in less developed nations. Each of the reported studies has taken us a small step forward. It is sure that, in the long run, heparin studies will pave the way toward advances in the treatment of sepsis. Hopefully, concurrent application of all these measures will help to considerably decrease the mortality of this lethal disease.
